Merck & Co., Inc. (MRK)
2 Blue-Chip Drug Stocks in Focus Today After Earnings
Stocks are struggling for direction today, and one sector that represents this choppiness is blue-chip drugmakers.
Merck (MRK) Tops Q4 Earnings and Revenue Estimates
Merck (MRK) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.69 per share. This compares to earnings of $0.03 per share a year ago.
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
On Tuesday, Merck & Co Inc MRK reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, sales increased 9%.
Merck's soft guidance overshadows quarterly beat to send stock down 6%
Merck's stock tumbled 6% early Tuesday, after the drug company's softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.
Merck's 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Merck on issued full-year 2025 revenue guidance that fell short of Wall Street's expectations. The company said that sales range reflects a decision to halt shipments of Gardasil, a vaccine that prevents cancer from HPV, into China beginning in February through and going through at least mid-2025.
Merck pauses Gardasil shipments to China, hitting its 2025 outlook
Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong fourth-quarter profit on sales of cancer drug Keytruda.
Gardasil Worries Loom as Merck Reports Earnings
Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
The Committee for Medicinal Products for Human Use recommends approval for Merck's pneumococcal 21-valent conjugate vaccine, Capvaxive.
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
MRK's decision to stop the late-stage HYPERION study on PAH drug Winrevair ahead of time comes after evaluating the drug's overall clinical program data.
Unveiling Merck (MRK) Q4 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.
